LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $105.80 Consensus Target Price from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $105.80.

Several research analysts recently issued reports on LMAT shares. Citizens Jmp lifted their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company boosted their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Roth Mkm reissued a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, March 10th.

LeMaitre Vascular Trading Down 4.6%

Shares of LeMaitre Vascular stock opened at $107.26 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular has a 1 year low of $78.01 and a 1 year high of $118.01. The company has a market capitalization of $2.45 billion, a P/E ratio of 42.73, a P/E/G ratio of 3.30 and a beta of 0.67. The business has a 50 day moving average price of $108.54 and a 200 day moving average price of $93.78.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same period in the previous year, the firm posted $0.49 EPS. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Sell-side analysts anticipate that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were given a dividend of $0.25 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is currently 39.84%.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This represents a 13.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David B. Roberts sold 8,464 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 215,438 shares of company stock valued at $23,062,911. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sound Income Strategies LLC boosted its position in LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 183 shares during the last quarter. Cornerstone Planning Group LLC boosted its position in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the last quarter. MAI Capital Management purchased a new position in LeMaitre Vascular in the 3rd quarter valued at about $38,000. First Horizon Corp purchased a new position in LeMaitre Vascular in the 3rd quarter valued at about $39,000. Finally, Geneos Wealth Management Inc. boosted its position in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.